therapeutics

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new…

11 months ago

Akari Therapeutics Releases Virtual Investor What This Means Segment Highlighting its Recently Granted India Patent

June 25, 2025 09:00 ET  | Source: Akari Therapeutics Plc Access the “What This Means” segment here BOSTON and LONDON,…

11 months ago

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation glucagon analogs and therapies to…

11 months ago

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib June 20,…

11 months ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in…

11 months ago

Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million

VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) --  Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),…

11 months ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 06, 2025 16:30 ET  | Source: Fulcrum Therapeutics, Inc. CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics,…

11 months ago

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

June 05, 2025 18:38 ET  | Source: Xilio Therapeutics, Inc. Total gross proceeds of up to $150.0 million before the…

11 months ago

AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B immunotherapy using Launch-iT technology

Third asset to advance into clinical trials, validating broad potential of Launch-iT platformAll subjects treated with first dose of AVX70371…

11 months ago

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today…

11 months ago